The Experts below are selected from a list of 51549 Experts worldwide ranked by ideXlab platform

J D Woodruff - One of the best experts on this subject based on the ideXlab platform.

  • Review of the granulosa-theca cell Tumors from the emil Novak Ovarian Tumor registry.
    American journal of obstetrics and gynecology, 1999
    Co-Authors: H S Cronjé, I Niemand, R H Bam, J D Woodruff
    Abstract:

    Our purpose was to review patients with granulosa and theca cell Tumors as filed in the Emil Novak Ovarian Tumor Registry. Our study was a descriptive, retrospective study of 454 case records. The reviewed diagnoses were for 97 patients with granulosa cell Tumors, 116 with theca cell Tumors, and 97 with granulosa-theca cell Tumors. The remaining cases (n = 144) were reclassified as "nonspecific" gonadal stromal Tumors (n = 61), luteomas of pregnancy (n = 7), and 76 "other" cases. These included poorly differentiated cancer, metastatic cancer, mixed mesodermal Tumors, and sarcomas. The Tumor-related mortality rate for the 310 patients with granulosa, theca, and granulosa-theca cell Tumors was 7% (37.3% for granulosa cell Tumors only). The surgical stage of disease was the most significant prognostic factor, with a mortality rate of at least 40%, given that the Tumor had spread beyond the ovary. Because the differential diagnoses of particularly granulosa cell Tumors included several conditions with an extremely poor prognosis, an accurate histologic diagnosis is crucial.

  • Review of the granulosa-theca cell Tumors from the emil Novak Ovarian Tumor registry.
    American Journal of Obstetrics and Gynecology, 1999
    Co-Authors: H S Cronjé, I Niemand, R H Bam, J D Woodruff
    Abstract:

    Abstract Objective: Our purpose was to review patients with granulosa and theca cell Tumors as filed in the Emil Novak Ovarian Tumor Registry. Study Design: Our study was a descriptive, retrospective study of 454 case records. Results: The reviewed diagnoses were for 97 patients with granulosa cell Tumors, 116 with theca cell Tumors, and 97 with granulosa-theca cell Tumors. The remaining cases (n = 144) were reclassified as "nonspecific" gonadal stromal Tumors (n = 61), luteomas of pregnancy (n = 7), and 76 "other" cases. These included poorly differentiated cancer, metastatic cancer, mixed mesodermal Tumors, and sarcomas. The Tumor-related mortality rate for the 310 patients with granulosa, theca, and granulosa-theca cell Tumors was 7% (37.3% for granulosa cell Tumors only). The surgical stage of disease was the most significant prognostic factor, with a mortality rate of at least 40%, given that the Tumor had spread beyond the ovary. Conclusion: Because the differential diagnoses of particularly granulosa cell Tumors included several conditions with an extremely poor prognosis, an accurate histologic diagnosis is crucial. (Am J Obstet Gynecol 1999;180:323-7.)

John J Kavanagh - One of the best experts on this subject based on the ideXlab platform.

  • metastasis to sigmoid colon mucosa and submucosa from serous borderline Ovarian Tumor response to hormone therapy
    International Journal of Gynecological Cancer, 2006
    Co-Authors: Michael T Deavers, J I Hughes, John J Kavanagh
    Abstract:

    .  Lee E-J, Deavers MT, Hughes JI, Lee J-H, Kavanagh JJ. Metastasis to sigmoid colon mucosa and submucosa from serous borderline Ovarian Tumor: response to hormone therapy. Int J Gynecol Cancer 2006;16(Suppl. 1):295–299. Distant metastasis to sites other than lymph nodes of borderline Ovarian Tumor is rare. We describe a case metastasized to sigmoid colon mucosa and submucosa. The metastatic lesion was detected incidentally by screening colonoscopy 7 years after the patient was treated for the primary Tumor. The metastatic lesion responded well to treatment with oral Arimidex 1 mg/day. A follow-up colonoscopy with biopsy and imaging studies after 3 months of treatment revealed no evidence of disease in the sigmoid colon. This case showed that the sigmoid colon mucosa and submucosa should be considered as one of distant metastatic sites of a serous borderline Ovarian Tumor and the favorable response to Arimidex provides support the use of hormone therapy in women with serous borderline Ovarian Tumor.

  • Metastasis to sigmoid colon mucosa and submucosa from serous borderline Ovarian Tumor: response to hormone therapy
    International Journal of Gynecologic Cancer, 2006
    Co-Authors: Michael T Deavers, J I Hughes, John J Kavanagh
    Abstract:

    Distant metastasis to sites other than lymph nodes of borderline Ovarian Tumor is rare. We describe a case metastasized to sigmoid colon mucosa and submucosa. The metastatic lesion was detected incidentally by screening colonoscopy 7 years after the patient was treated for the primary Tumor. The metastatic lesion responded well to treatment with oral Arimidex 1 mg/day. A follow-up colonoscopy with biopsy and imaging studies after 3 months of treatment revealed no evidence of disease in the sigmoid colon. This case showed that the sigmoid colon mucosa and submucosa should be considered as one of distant metastatic sites of a serous borderline Ovarian Tumor and the favorable response to Arimidex provides support the use of hormone therapy in women with serous borderline Ovarian Tumor.

H S Cronjé - One of the best experts on this subject based on the ideXlab platform.

  • Review of the granulosa-theca cell Tumors from the emil Novak Ovarian Tumor registry.
    American journal of obstetrics and gynecology, 1999
    Co-Authors: H S Cronjé, I Niemand, R H Bam, J D Woodruff
    Abstract:

    Our purpose was to review patients with granulosa and theca cell Tumors as filed in the Emil Novak Ovarian Tumor Registry. Our study was a descriptive, retrospective study of 454 case records. The reviewed diagnoses were for 97 patients with granulosa cell Tumors, 116 with theca cell Tumors, and 97 with granulosa-theca cell Tumors. The remaining cases (n = 144) were reclassified as "nonspecific" gonadal stromal Tumors (n = 61), luteomas of pregnancy (n = 7), and 76 "other" cases. These included poorly differentiated cancer, metastatic cancer, mixed mesodermal Tumors, and sarcomas. The Tumor-related mortality rate for the 310 patients with granulosa, theca, and granulosa-theca cell Tumors was 7% (37.3% for granulosa cell Tumors only). The surgical stage of disease was the most significant prognostic factor, with a mortality rate of at least 40%, given that the Tumor had spread beyond the ovary. Because the differential diagnoses of particularly granulosa cell Tumors included several conditions with an extremely poor prognosis, an accurate histologic diagnosis is crucial.

  • Review of the granulosa-theca cell Tumors from the emil Novak Ovarian Tumor registry.
    American Journal of Obstetrics and Gynecology, 1999
    Co-Authors: H S Cronjé, I Niemand, R H Bam, J D Woodruff
    Abstract:

    Abstract Objective: Our purpose was to review patients with granulosa and theca cell Tumors as filed in the Emil Novak Ovarian Tumor Registry. Study Design: Our study was a descriptive, retrospective study of 454 case records. Results: The reviewed diagnoses were for 97 patients with granulosa cell Tumors, 116 with theca cell Tumors, and 97 with granulosa-theca cell Tumors. The remaining cases (n = 144) were reclassified as "nonspecific" gonadal stromal Tumors (n = 61), luteomas of pregnancy (n = 7), and 76 "other" cases. These included poorly differentiated cancer, metastatic cancer, mixed mesodermal Tumors, and sarcomas. The Tumor-related mortality rate for the 310 patients with granulosa, theca, and granulosa-theca cell Tumors was 7% (37.3% for granulosa cell Tumors only). The surgical stage of disease was the most significant prognostic factor, with a mortality rate of at least 40%, given that the Tumor had spread beyond the ovary. Conclusion: Because the differential diagnoses of particularly granulosa cell Tumors included several conditions with an extremely poor prognosis, an accurate histologic diagnosis is crucial. (Am J Obstet Gynecol 1999;180:323-7.)

Scott D Pegan - One of the best experts on this subject based on the ideXlab platform.

  • Diversity of Ubiquitin and ISG15 Specificity among Nairoviruses' Viral Ovarian Tumor Domain Proteases
    Journal of Virology, 2013
    Co-Authors: Glenn C. Capodagli, Michelle K. Deaton, Erica A. Baker, Ryan J Lumpkin, Scott D Pegan
    Abstract:

    Nairoviruses are responsible for numerous diseases that affect both humans and animal. Recent work has implicated the viral Ovarian Tumor domain (vOTU) as a possible nairovirus virulence factor due to its ability to edit ubiquitin (Ub) bound to cellular proteins and, at least in the case of Crimean-Congo hemorrhagic fever virus (CCHFV), to cleave the Ub-like protein interferon-stimulated gene 15 (ISG15), a protein involved in the regulation of host immunity. The prospective roles of vOTUs in immune evasion have generated several questions concerning whether vOTUs act through a preserved specificity for Ub- and ISG15-conjugated proteins and where that specificity may originate. To gain insight into the substrate specificity of vOTUs, enzymological studies were conducted on vOTUs from Dugbe, CCHFV, and Erve nairoviruses. These studies revealed that vOTUs originating from different nairoviruses display a significant divergence in their preference toward Ub and ISG15. In addition, a recently identified vOTU from turnip yellow mosaic tymovirus was evaluated to elucidate any possible similarities between vOTUs originating from different viral families. Although possessing a similar preference for certain polymeric Ub moieties, its activity toward Ub in general was significantly less then those of nairoviruses. Lastly, the X-ray crystallographic structure of the vOTU from the Dugbe nairovirus was obtained in complex with Ub to reveal structural commonalities of vOTUs originating from nairoviruses. The structure suggests that divergences between nairovirus vOTUs specificity originate at the primary structural level. Comparison of this structure to that originating from CCHFV identified key residues that infer the substrate specificity of vOTUs.

Michael T Deavers - One of the best experts on this subject based on the ideXlab platform.

  • metastasis to sigmoid colon mucosa and submucosa from serous borderline Ovarian Tumor response to hormone therapy
    International Journal of Gynecological Cancer, 2006
    Co-Authors: Michael T Deavers, J I Hughes, John J Kavanagh
    Abstract:

    .  Lee E-J, Deavers MT, Hughes JI, Lee J-H, Kavanagh JJ. Metastasis to sigmoid colon mucosa and submucosa from serous borderline Ovarian Tumor: response to hormone therapy. Int J Gynecol Cancer 2006;16(Suppl. 1):295–299. Distant metastasis to sites other than lymph nodes of borderline Ovarian Tumor is rare. We describe a case metastasized to sigmoid colon mucosa and submucosa. The metastatic lesion was detected incidentally by screening colonoscopy 7 years after the patient was treated for the primary Tumor. The metastatic lesion responded well to treatment with oral Arimidex 1 mg/day. A follow-up colonoscopy with biopsy and imaging studies after 3 months of treatment revealed no evidence of disease in the sigmoid colon. This case showed that the sigmoid colon mucosa and submucosa should be considered as one of distant metastatic sites of a serous borderline Ovarian Tumor and the favorable response to Arimidex provides support the use of hormone therapy in women with serous borderline Ovarian Tumor.

  • Metastasis to sigmoid colon mucosa and submucosa from serous borderline Ovarian Tumor: response to hormone therapy
    International Journal of Gynecologic Cancer, 2006
    Co-Authors: Michael T Deavers, J I Hughes, John J Kavanagh
    Abstract:

    Distant metastasis to sites other than lymph nodes of borderline Ovarian Tumor is rare. We describe a case metastasized to sigmoid colon mucosa and submucosa. The metastatic lesion was detected incidentally by screening colonoscopy 7 years after the patient was treated for the primary Tumor. The metastatic lesion responded well to treatment with oral Arimidex 1 mg/day. A follow-up colonoscopy with biopsy and imaging studies after 3 months of treatment revealed no evidence of disease in the sigmoid colon. This case showed that the sigmoid colon mucosa and submucosa should be considered as one of distant metastatic sites of a serous borderline Ovarian Tumor and the favorable response to Arimidex provides support the use of hormone therapy in women with serous borderline Ovarian Tumor.